Centrexion Therapeutics Corporation  announced that it will receive $16,475,000 in funding on May 24, 2022. The company will issue convertible debt and option, warrant or other right to acquire another security in the transaction. The company will issue securities pursuant to exemption provided under Regulation D. Maxim Group LLC will act as finder in the transaction and will receive fees of $1,482,750 in cash, approximately 269,092 shares and a warrant to purchase up to 988,500 shares.